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This study validated a high performance liquid chromatography (HPLC) method for the quantitative evaluation of quercetin in topical 
emulsions. The method was linear within 0.05 – 200 µg/mL range with a correlation coefficient of 0.9997, and without interference 
in the quercetin peak. The detection and quantitation limits were 18 and 29 ng/mL, respectively. The intra- and inter-assay precisions 
presented R.S.D. values lower than 2%. An average of 93% and 94% of quercetin was recovered for non-ionic and anionic emulsions, 
respectively. The raw material and anionic emulsion, but not non-ionic emulsion, were stable in all storage conditions for one year. 
The method reported is a fast and reliable HPLC technique useful for quercetin determination in topical emulsions.
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INTRODUCTION
Reactive oxygen species (ROS) including free radicals such as 
superoxide anion radicals (O2-•), hydroxyl radical species (•OH), and 
hydrogen peroxide (H2O2) are active oxygen compounds often gene-
rated by biological oxidative reactions, and induced by exogenous 
factors1 such as excessive sun exposure and increased air pollution.
In this context, antioxidants from natural products provide 
novel perspectives for the treatment and prevention of oxidative 
stress-mediated skin diseases by inhibiting or scavenging free 
radicals.2,3 Researches have been focused on the potential use 
of these drugs as free radical scavengers, especially for topical 
application to prevent oxidative skin damages.4,5 Quercetin is one 
of the major flavonoids found in foods like onions, apples, and 
teas. Its use in topical emulsion reduces UVB-induced oxidative 
and inflammatory skin damages.6
High performance liquid chromatography (HPLC) is a useful 
tool to analyze samples of complex nature like ointments and creams, 
because it provides not only the separation and determination, but 
also eliminates most interference problems.7 The first demonstration 
of the applicability of HPLC to determine flavonoids was in 1976,8 
and since then, several studies have described the validation of HPLC 
methods for quantifying flavonoids. However, most of them focused 
on their separation in food, medicinal plants or biological fluids. For 
instance, a validated HPLC method was used to separate and quan-
tify three main flavonoids from the plant Achyrocline satureioides.9 
Demonstration of HPLC assays to separate and quantify flavonoids 
aglycones from typical foods,8 as well as, to detect flavonoids in 
orange juice have also been reported.10 
The aim of the present study was to validate an isocratic HPLC 
method for the determination of quercetin in topical emulsions as 
well as to evaluate physico-chemical stability of two proposed for-
mulations, a nonionic one and another anionic.
EXPERIMENTAL
Materials
Quercetin was obtained from Acros (New Jersey, USA) and 
used as standard. Raw materials for formulations were obtained 
from Galena (Campinas, SP, Brazil). All other reagents used were 
pharmaceutical or chromatographic grade.
Formulations
A non-ionic emulsion (formulation 1) was prepared with commer-
cially available self-emulsifying wax (10%, Polawax® – cetostearyl 
alcohol and polyoxyethylene derived of a fatty acid ester of sorbitan 
20E); and an anionic emulsion (formulation 2) was prepared with 
Polawax® (2%), an anionic hydrophilic colloid (0.18%, carboxy-
polymethylene, Carbopol® 940) served as a stabilizing agent and 
triethanolamine (0.2%) as neutralizant. Macadamia nut oil (2.5%) 
and squalene (1%) were added as emollients, and propyleneglycol 
(6%) as a moisturizer and solubilizer. The preservative used was a 
mixture of phenoxyethanol and parabens (0.4%, Phenova®). Deioni-
zed water was used to complete 100% (w/w) in the preparation of all 
formulations. Quercetin (0.05%) was solubilized in propyleneglycol 
and then added to the formulations at room temperature. Control 
formulations did not contain the flavonoid. All formulations were 
allowed to equilibrate for 24 h prior to use. 
Chromatographic conditions
The chromatographic system consisted of a Shimadzu LC-10AT 
equipped with a 20 µL loop and SPD-10A UV/VIS detector. Integration 
of the chromatographic peaks was achieved with C-R6A Chromatopac 
integrator (Shimadzu Corporation, Tokyo, Japan). Chromatography was 
performed on a Hypersil® BDS-CPS C18 column (5 µm; 250 x 4.6 mm 
i.d.; Thermo Quest – Hypersil Division, Runcorn, UK) with a mobile 
Casagrande et al.1940 Quim. Nova
phase of methanol: water (35:65; v/v) containing 2% acetic acid and 
flow rate of 1 mL/min. Each sample was prepared in triplicate. The 
volume injected was 20 µL with detection at 254 nm.11
Preparation of standard solutions
Standard quercetin was dissolved in methanol obtaining a solution 
of 1000 µg of quercetin per mL of methanol. Then, this methanolic 
quercetin solution was diluted with mobile phase to yield the following 
concentrations: 0.05, 0.5, 1, 2, 5, 10, 25, 50, 100 and 200 µg/mL.
Preparation of formulation samples
Accurately weighed 0.5 g of formulations 1 and 2 containing the 
equivalent to 0.25 mg of quercetin were transferred to 10 mL volume-
tric flasks which were completed with methanol. These solutions were 
25-fold diluted in mobile phase yielding solutions at the quercetin 
concentration of 1 µg/mL. The same procedure was performed for 
control formulations 1 and 2. 
Method validation
The validation was performed based on the ICH Guidance,12 taking 
into account the parameters required for assaying dosage forms. 
Specificity
The specificity of the method was evaluated by analyzing solu-
tions of the control formulations 1 and 2. The samples were prepared 
as described in the preparation of formulation samples section, and 
analyzed as described in the chromatographic conditions. All analyses 
were performed in triplicate. The system response was examined 
through the presence of interference or overlaps with the quercetin 
formulations responses.
Linearity
For linearity experiments, solutions of quercetin were prepared at 
ten concentrations within the range of 0.05-200 µg/mL in 3 different 
days as described in the preparation of standard solutions section. The 
solutions were prepared in triplicate. The linearity was evaluated by 
linear regression analysis, which was calculated by the least square 
regression method.
Limit of detection and limit of quantitation
The limit of detection (LOD) and limit of quantitation (LOQ) 
parameters were determined on the basis of peak height and the slope 
of the regression equation. Analysis was performed in triplicate.
Precision
The precision of the assay was determined by repeatability (intra-
assay) and intermediate precision (inter-assay). Repeatability was 
evaluated by analysis of three determinations at different concentrations 
(0.5, 1 and 2 µg/mL, in triplicate), in the same day under the same expe-
rimental conditions. The intermediate precision was studied by assaying 
freshly prepared solutions of quercetin on three different days.
Accuracy
The accuracy experiments were performed applying the method to 
quantify quercetin in the presence of excipients of formulations. The 
control formulations were prepared as described in the preparation 
of formulation samples section, then, a known amount of quercetin 
(10 µg/mL) was added. Afterwards, samples were 10 fold diluted in 
mobile phase (1 µg/mL), filtered and analyzed. The results represent 
the mean of recovery for three independent samples.
Physico-chemical stability evaluation
Physico-chemical stability was evaluated by submitting the 
formulations to storage at 4 °C, controlled room temperature (RT, 
25 °C), 37 °C, and 45 °C during 365 days.13 Samples were collected 
at pre-determined time intervals for pH, centrifugation, optical mi-
croscopic analyses and evaluation of quercetin concentration.
To determine the pH, formulations were diluted 1:10 in deio-
nized water and the analysis was performed in a Digmed pH meter 
apparatus. For the centrifugation assay, samples of the formulations 
were centrifuged at 3000 rpm for 30 min at room temperature. Phase 
separation was visually analyzed, and globule size was evaluated 
using a Leica DMLB microscope equipped with a Leica DC 300 
camera.14
To determine the quercetin concentration, the raw material was 
dissolved in methanol (1000 µg/mL) and diluted 1000 fold in the 
mobile phase to obtain a concentration of 1 µg of quercetin per mL. 
The same dilution procedure was performed for the formulations 
with quercetin and control formulations, i.e. first dilution in methanol 
and thereafter in mobile phase, obtaining the same concentration of 
quercetin (1 µg/mL) used in the analysis of raw material. All measu-
rements were performed in triplicate. 
Statistical analysis
Data were statistically analyzed by one-way ANOVA, followed 
by Bonferroni’s multiple comparisons t-test for evaluation of storage 
conditions influence in the globule size of formulations 1 and 2. Re-
sults were presented as mean ± SEM (standard error of the mean) and 
considered significantly different when P < 0.05 was obtained.
RESULTS AND DISCUSSION
Topical administration of antioxidants is an efficient way to enrich 
the endogenous cutaneous system of protection, and thus, a successful 
strategy to decrease oxidative damage of the skin by ultraviolet irra-
diation.15 Quercetin is a promising compound to combat free radical 
diseases such as cancer and inflammatory conditions. Furthermore, 
its topical effectiveness to protect the skin from oxidative stress has 
been recently demonstrated,6,13,16 which reinforces the importance of 
quality control of topical formulation containing quercetin. In this 
sense, this work demonstrates one of the most valuable tools in the 
pharmaceutical analysis of quality control,11 which is a HPLC assay 
for the analysis of quercetin in topical formulations. 
Firstly, analytical experiments addressed whether the excipients of 
formulations would interfere over quercetin quantification since emul-
sions are made of lipidic and aqueous components. The specificity was 
carried out through the comparison of the peak retention time of the 
formulations with quercetin and control formulations. No interference 
of the emulsion excipients was detected since no peak was detected in 
the same retention time of quercetin (Figures 1 A, B, C and D). In the 
employed chromatographic conditions, quercetin presented a reten-
tion time of approximately 8.9 minutes for formulations 1 and 2, thus, 
allowing a rapid determination of the drug that is essential for routine 
analysis.17 Further confirming no interference of emulsion excipients, 
Figure 1 E shows the chromatogram of standard quercetin presenting 
the same retention time as detected in Figures 1 B and D.
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Analytical curves for quercetin were fitted by plotting concentra-
tion versus the corresponding mean peak height. Satisfactory linearity 
was detected in the 0.05 – 200 µg/mL range. The representative linear 
equation was y = 4022.5x-265.43, with a highly significant correlation 
coefficient (r = 0.9997) for the method. The detection and quantita-
tion limits were calculated based on the standard deviation of the 
peak height and the slopes of the calibration curves. The values were 
found to be 18 ± 0.53 and 29 ± 0.97 ng/mL, respectively, indicating 
the high sensitivity of the method.17
The precision of the method was determined by repeatability 
(intra-assay) and intermediate precision (inter-assay), and shown 
as the relative standard deviation (R.S.D) in Table 1. The intra- and 
inter-assay precisions presented R.S.D. values lower than 2%, which 
were satisfactory for the purpose of the analysis.12 The accuracy of 
the method was determined and the mean recoveries were 93 and 
94% for formulations 1 and 2, respectively.
The stability evaluation of formulation’s active principle stored at 
different climatic conditions for given times constitutes an important 
step for the development of novel products. It provides information 
concerning to the shelf-life of pharmaceutical products and conditions 
for their storage.13,18 Emulsions must be tested at widely varying 
temperatures in order to ensure that the product will remain stable 
throughout all possible conditions. For accelerated temperature tes-
ting, it is important to remember that temperature stability protocols 
depend on product category. Studies may range from freezing to 
very high temperatures and/or cycling between various temperatures. 
Generally, emulsions are stored at −10 °C or 4 °C, RT, 37 °C, and 
45 °C or 50 °C.13,18
Table 2 shows the initial observations obtained for pH values, 
centrifugation and globule size for formulations containing or not 
quercetin. It is necessary to control the pH of formulations since it 
must remain compatible with the components of formulation and 
with the application site, thus, avoiding irritation.14 During the one 
year-period of study, the formulations 1 and 2 showed a pH range 
of 5.10-5.40 and 6.84–7.16, respectively, which are compatible with 
topical use (Table 2).
The centrifugation test is of major interest since it provides 
fast information about comparable stability properties of different 
emulsions. It is consensus that physical stability of emulsions un-
der normal storage conditions is rapidly predictable by observing 
the separation of the dispersed phase due to either creaming or 
coalescence when the emulsion is centrifuged. This test is specially 
employed to evaluate emulsions stability during pre-formulation 
stage, thus, can be useful to detect alterations during storage.14 
Formulations 1 and 2 were stable since there was no separation of 
phases (Table 2). 
Figure 1. Chromatograms of control formulation 1 (A) and formulation 1 with 
quercetin (B), control formulation 2 (C) and formulation 2 with quercetin (D) 
and standard quercetin (E). Chromatographic conditions: Hypersil® BDS-CPS 
C18 column, 250 x 4.6 mm attached to a pre-column, mobile phase: methanol: 
water (35:65; v/v) containing 2% acetic acid, 1 mL/min
Table 1. Intra-assay and inter-assay precision for HPLC determina-
tion of quercetin 
Precision
Conc. (µg/mL) Intra-assay Inter-assay
(RSD)a (RSD)
0.5 0.56 – 1.23 0.96
1.0 0.042 – 1.47 1.51
2.0 0.79 – 1.51 0.67
aRSD, Relative standard deviation in 3 days of validation
Table 2. Influence of 1 year of storage at 45 °C on the physico-chemical stability of topical formulations containing or not quercetin
Formulation pH Centrifugation Globule size (µm2)
Initial 1 year Initial 1 year Initial 1 year
Control formulation 1 5.20 5.10 NS NS 12.31 ± 1.77 10.59 ± 2.40
Formulation 1 + quercetin 5.40 5.32 NS NS 11.18 ± 2.32 13.18 ± 2.77
Control formulation 2 7.01 6.84 NS NS 18.45 ± 3.97 9.46 ± 1.92
Formulation 2 + quercetin 7.08 7.16 NS NS 16.34 ± 2.85 9.56 ± 2.20
NS: no separation. No statistical significant differences were detected in the globule size.
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The measurement of the globules size initially and during storage 
also provides an indication of the stability of the system, because 
the globules size increase indicates instability of the system. Several 
methods can be employed to measure globule size, being optical mi-
croscopy a common way of measuring the size of emulsion globules.14 
Table 2 shows, as an example, the initial globule size and after one 
year of storage at 45 °C. Other storage conditions are not shown since 
there were no statistical differences between initial and one year-
period storage at all temperatures tested. Smaller globules size were 
detected in formulation 1 compared to formulation 2 (Table 2). This 
is probably due to the higher content of surfactants in formulation 1. 
However, it seems that the globules size was not a major determinant 
and/or did not influence the quercetin stability since there was no 
modification in the globule size during the storage period.
The determination of quercetin content was used to evaluate the 
stability of the raw material and formulations over different condi-
tions as shown in Figure 2. The raw material remained stable in 
all conditions during one year of storage. The major loss of initial 
quercetin content after one year was 48% for formulation 1 and 8% 
for formulation 2 at 45 °C. Therefore, in order to guarantee stability 
during shelf-life of formulation 1, it is recommended to avoid exces-
sive heat (45 °C) or refrigeration exposure for prolonged periods. A 
safer action is to predict 50% less time for stability in case formulation 
1 is not properly stored, thus, a 180 day-shelf-life period.
Concluding, the present work reports a fast and reliable HPLC 
technique useful for routine quality control for quercetin determina-
tion in topical formulations.
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Figure 2. Percentage of quercetin found in raw material (A), formulations 1 
(B) and 2 (C) following storage at 4 °C, RT (25 °C), 37 °C and 45 °C for 365 
days. The initial concentration of quercetin was 1 µg/mL for raw material, 
formulation 1 and formulation 2 solutions. Results are represented by mean 
± standard error of the mean (SEM)
